Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from VentriPoint Diagnostics ( (TSE:VPT) ) is now available.
Ventripoint Diagnostics has issued 291,344 common shares, valued at a deemed price of $0.127, to settle $36,989.01 in interest owed on several outstanding convertible debenture series, following approval from the TSX Venture Exchange. The shares, which carry a four-month-plus-one-day hold, will not result in the creation of a new control shareholder, indicating a relatively limited dilution impact for existing investors.
The company also reported that the debentures issued on January 17, 2025 and February 7, 2025, totalling $256,000, have been fully converted, eliminating any further interest obligations on those instruments. This combination of share-for-interest payment and debenture conversions signals an ongoing effort to manage financing costs and simplify Ventripoint’s capital structure as it advances its AI-driven cardiac imaging business.
The most recent analyst rating on (TSE:VPT) stock is a Hold with a C$0.12 price target. To see the full list of analyst forecasts on VentriPoint Diagnostics stock, see the TSE:VPT Stock Forecast page.
Spark’s Take on TSE:VPT Stock
According to Spark, TipRanks’ AI Analyst, TSE:VPT is a Neutral.
The score is held back primarily by weak financial fundamentals (ongoing losses, cash burn, and negative equity). Technicals are moderately constructive with improving momentum, and corporate updates are directionally positive, but valuation support is limited due to negative earnings and no dividend indicated.
To see Spark’s full report on TSE:VPT stock, click here.
More about VentriPoint Diagnostics
Ventripoint Diagnostics Ltd. is a medical technology company specializing in applying artificial intelligence to echocardiography to deliver MRI-equivalent volumetric cardiac measurements. Its VMS and VMS+ systems provide an affordable, gold-standard alternative for cardiologists and are compatible with all major ultrasound platforms, with regulatory approvals in the U.S., Europe and Canada.
Average Trading Volume: 142,493
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$19.67M
For a thorough assessment of VPT stock, go to TipRanks’ Stock Analysis page.